Related references
Note: Only part of the references are listed.Shift From Adalimumab Originator to Biosimilars in Denmark
Thomas Bo Jensen et al.
JAMA INTERNAL MEDICINE (2020)
Molecular and Biological Functions of Quercetin as a Natural Solution for Cardiovascular Disease Prevention and Treatment
Liaosadat Mirsafaei et al.
PLANT FOODS FOR HUMAN NUTRITION (2020)
Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications A Systematic Review and Network Meta-analysis
Jingkai Wei et al.
JAMA NETWORK OPEN (2020)
Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis
Stephen Robert Chapman et al.
BMJ OPEN (2019)
The Effects of a New Public Medicine Procurement Policy on Medicine Price in Shaanxi Province, Western China: An Interrupted Time Series Analysis
Shuchen Hu et al.
FRONTIERS IN PHARMACOLOGY (2019)
The Impacts of Drug Price Regulations in China
Yi Liu et al.
JOURNAL OF SYSTEMS SCIENCE AND SYSTEMS ENGINEERING (2019)
The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period
Olivier J. Wouters et al.
SOCIAL SCIENCE & MEDICINE (2019)
4+7 city drug volume-based purchasing and using pilot program in China and its impact
Mi Tang et al.
DRUG DISCOVERIES AND THERAPEUTICS (2019)
Pharmaceutical Policy Reforms to Regulate Drug Prices in the Asia Pacific Region: The Case of Australia, China, India, Malaysia, New Zealand, and South Korea
Syed Shahzad Hasan et al.
VALUE IN HEALTH REGIONAL ISSUES (2019)
Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing
Wenxi Tang et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage
Nikolaos Maniadakis et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2018)
Effects of Public Hospital Reform on Inpatient Expenditures in Rural China
Yuting Zhang et al.
HEALTH ECONOMICS (2017)
Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance
Mingyue Zhao et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2017)
Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China
Yuqing Tang et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis
Junjie Liu et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2017)
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
Sabine Vogler et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts
Jia Hu et al.
HEALTH POLICY (2016)
Public reporting as a prescriptions quality improvement measure in primary care settings in China: variations in effects associated with diagnoses
Yuqing Tang et al.
SCIENTIFIC REPORTS (2016)
Prescribing efficiency of proton pump inhibitors in China: influence and future directions
Wenjie Zeng et al.
BMC HEALTH SERVICES RESEARCH (2015)
Effects of pharmaceutical price regulation: China's evidence between 1997 and 2008
Binzhen Wu et al.
JOURNAL OF THE ASIA PACIFIC ECONOMY (2015)
Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study
Giovanni Corrao et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals
Jing Wu et al.
PHARMACOECONOMICS (2014)
Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction
Wenjie Zeng et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2014)
Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy
Jean Spinks et al.
AUSTRALIAN HEALTH REVIEW (2013)
A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China
Wenjie Zeng
BMC HEALTH SERVICES RESEARCH (2013)
Reforming antiretroviral price negotiations and public procurement: the Mexican experience
Adebiyi Adesina et al.
HEALTH POLICY AND PLANNING (2013)
Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis
Nathalie Vernaz et al.
PLOS MEDICINE (2013)
Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China
Yu Fang et al.
LANCET GLOBAL HEALTH (2013)
Generic Medicines: Solutions for a Sustainable Drug Market?
Pieter Dylst et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
A new entity for the negotiation of public procurement prices for patented medicines in Mexico
Octavio Gomez-Dantes et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2012)
Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications
Menno van Woerkom et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2012)
Essential medicine policy in China: pros and cons
Shanlian Hu
JOURNAL OF MEDICAL ECONOMICS (2012)
Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?
Pieter Dylst et al.
HEALTH POLICY (2011)
Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration
Barbara M. Davit et al.
ANNALS OF PHARMACOTHERAPY (2009)
The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals
QY Meng et al.
HEALTH POLICY AND PLANNING (2005)
Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country
DR Milovanovic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Share Paper
